{"id":"https://openalex.org/W3082864643","doi":"https://doi.org/10.1002/cpt.2029","title":"Time for a Fully Integrated Nonclinical\u2013Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective","display_name":"Time for a Fully Integrated Nonclinical\u2013Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective","publication_year":2020,"publication_date":"2020-08-31","ids":{"openalex":"https://openalex.org/W3082864643","doi":"https://doi.org/10.1002/cpt.2029","mag":"3082864643","pmid":"https://pubmed.ncbi.nlm.nih.gov/32866317","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7891594"},"language":"en","primary_location":{"id":"doi:10.1002/cpt.2029","doi":"https://doi.org/10.1002/cpt.2029","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpt.2029","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpt.2029","source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpt.2029","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001580477","display_name":"Hugo M. Vargas","orcid":"https://orcid.org/0000-0001-9447-3164","observed_orcids":["https://orcid.org/0000-0001-9447-3164"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Hugo M. Vargas","raw_affiliation_strings":["Translational Safety & Bioanalytical Sciences, Amgen Research, Thousand Oaks, California, USA"],"raw_orcid":"https://orcid.org/0000-0001-9447-3164","affiliations":[{"raw_affiliation_string":"Translational Safety & Bioanalytical Sciences, Amgen Research, Thousand Oaks, California, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081400159","display_name":"Michael G. Rolf","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Michael G. Rolf","raw_affiliation_strings":["Research & Development, Clinical Pharmacology & Safety Sciences AstraZeneca Gothenburg Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research & Development, Clinical Pharmacology & Safety Sciences AstraZeneca Gothenburg Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034933041","display_name":"Todd A. Wisialowski","orcid":"https://orcid.org/0000-0002-1040-7512","observed_orcids":["https://orcid.org/0000-0002-1040-7512"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Todd A. Wisialowski","raw_affiliation_strings":["Global Safety Pharmacology, Pfizer Global Research and Development, Groton, Connecticut, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Safety Pharmacology, Pfizer Global Research and Development, Groton, Connecticut, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071294871","display_name":"William E. Achanzar","orcid":"https://orcid.org/0000-0002-5333-7374","observed_orcids":["https://orcid.org/0000-0002-5333-7374"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Achanzar","raw_affiliation_strings":["BMS Bristol-Myers Squibb Company, Princeton, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BMS Bristol-Myers Squibb Company, Princeton, New Jersey, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038826323","display_name":"Anthony Bahinski","orcid":"https://orcid.org/0000-0002-2379-6027","observed_orcids":["https://orcid.org/0000-0002-2379-6027"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony Bahinski","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, Pennsylvania, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, Pennsylvania, USA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112560912","display_name":"Alan S. Bass","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alan Bass","raw_affiliation_strings":["Merck & Co., Inc. Boston Massachusetts USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. Boston Massachusetts USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023603655","display_name":"Charles Benson","orcid":"https://orcid.org/0000-0002-7681-5746","observed_orcids":["https://orcid.org/0000-0002-7681-5746"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles T Benson","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084104321","display_name":"Khuram W. Chaudhary","orcid":"https://orcid.org/0000-0001-5693-0491","observed_orcids":["https://orcid.org/0000-0001-5693-0491"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Khuram W. Chaudhary","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, Pennsylvania, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, Pennsylvania, USA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073564208","display_name":"Nicolas Couvreur","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268767","display_name":"Institut de Recherches Internationales Servier (France)","ror":"https://ror.org/01zej3n42","country_code":"FR","type":"company","lineage":["https://openalex.org/I4405268767"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Nicolas Couvreur","raw_affiliation_strings":["Safety Pharmacology, Institute de Recherches Servier, Suresnes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Safety Pharmacology, Institute de Recherches Servier, Suresnes, France","institution_ids":["https://openalex.org/I4405268767"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048278940","display_name":"Corina Dota","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Corina Dota","raw_affiliation_strings":["Research & Development, Chief Medical Officer Organization AstraZeneca Gothenburg Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research & Development, Chief Medical Officer Organization AstraZeneca Gothenburg Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110445407","display_name":"Michael J. Engwall","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J Engwall","raw_affiliation_strings":["Translational Safety & Bioanalytical Sciences, Amgen Research, Thousand Oaks, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Translational Safety & Bioanalytical Sciences, Amgen Research, Thousand Oaks, California, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066532180","display_name":"C. Michael Foley","orcid":"https://orcid.org/0009-0001-1709-6104","observed_orcids":["https://orcid.org/0009-0001-1709-6104"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Michael Foley","raw_affiliation_strings":["Integrative Pharmacology, Abbvie, Inc, North Chicago, Illinois, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integrative Pharmacology, Abbvie, Inc, North Chicago, Illinois, USA","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101456329","display_name":"David J. Gallacher","orcid":"https://orcid.org/0000-0003-2548-3056","observed_orcids":["https://orcid.org/0000-0003-2548-3056"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"David Gallacher","raw_affiliation_strings":["Global Safety Pharmacology Janssen Research & Development Beerse Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Safety Pharmacology Janssen Research & Development Beerse Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064835358","display_name":"Andrea Greiter\u2010Wilke","orcid":"https://orcid.org/0000-0002-6460-5135","observed_orcids":["https://orcid.org/0000-0002-6460-5135"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Andrea Greiter\u2010Wilke","raw_affiliation_strings":["Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110445510","display_name":"Jean\u2010Michel Guillon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018075036","display_name":"Sanofi (France)","ror":"https://ror.org/02n6c9837","country_code":"FR","type":"company","lineage":["https://openalex.org/I3018075036"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jean\u2010Michel Guillon","raw_affiliation_strings":["Sanofi R&D, Preclinical Safety Paris France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi R&D, Preclinical Safety Paris France","institution_ids":["https://openalex.org/I3018075036"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109830894","display_name":"Brian D. Guth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Brian Guth","raw_affiliation_strings":["Department of Drug Discovery Sciences Boehringer Ingelheim Pharma GmbH & Co. KG Biberach an der Riss Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Drug Discovery Sciences Boehringer Ingelheim Pharma GmbH & Co. KG Biberach an der Riss Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110373779","display_name":"Herbert M. Himmel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67348948","display_name":"Bayer (Germany)","ror":"https://ror.org/04hmn8g73","country_code":"DE","type":"company","lineage":["https://openalex.org/I67348948"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Herbert M. Himmel","raw_affiliation_strings":["Safety Pharmacology, Bayer AG, Wuppertal, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Safety Pharmacology, Bayer AG, Wuppertal, Germany","institution_ids":["https://openalex.org/I67348948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046099632","display_name":"Christa Hegele\u2010Hartung","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67348948","display_name":"Bayer (Germany)","ror":"https://ror.org/04hmn8g73","country_code":"DE","type":"company","lineage":["https://openalex.org/I67348948"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Christa Hegele\u2010Hartung","raw_affiliation_strings":["Safety Pharmacology, Bayer AG, Wuppertal, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Safety Pharmacology, Bayer AG, Wuppertal, Germany","institution_ids":["https://openalex.org/I67348948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110005643","display_name":"Maki Ito","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405255266","display_name":"Japan Pharmaceutical Manufacturers Association","ror":"https://ror.org/02t1m5632","country_code":"JP","type":"nonprofit","lineage":["https://openalex.org/I4405255266"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Maki Ito","raw_affiliation_strings":["Japan Pharmaceutical Manufacturers Association, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Japan Pharmaceutical Manufacturers Association, Tokyo, Japan","institution_ids":["https://openalex.org/I4405255266"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031121778","display_name":"Stephen G. Jenkinson","orcid":"https://orcid.org/0000-0003-3880-236X","observed_orcids":["https://orcid.org/0000-0003-3880-236X"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Jenkinson","raw_affiliation_strings":["Global Safety Pharmacology, Pfizer Global Research and Development, San Diego, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Safety Pharmacology, Pfizer Global Research and Development, San Diego, California, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046959175","display_name":"Katsuyoshi Chiba","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Katsuyoshi Chiba","raw_affiliation_strings":["Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045441577","display_name":"Armando Lagrutta","orcid":"https://orcid.org/0000-0002-0136-6210","observed_orcids":["https://orcid.org/0000-0002-0136-6210"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Armando Lagrutta","raw_affiliation_strings":["Merck & Co., Inc. West Point Pennsylvania USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc. West Point Pennsylvania USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033913734","display_name":"Paul L\u00e9vesque","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Levesque","raw_affiliation_strings":["BMS Bristol-Myers Squibb Company, Princeton, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BMS Bristol-Myers Squibb Company, Princeton, New Jersey, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055306952","display_name":"Eric Martel","orcid":"https://orcid.org/0000-0001-8015-7283","observed_orcids":["https://orcid.org/0000-0001-8015-7283"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Eric Martel","raw_affiliation_strings":["Department of Drug Discovery Sciences Boehringer Ingelheim Pharma GmbH & Co. KG Biberach an der Riss Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Drug Discovery Sciences Boehringer Ingelheim Pharma GmbH & Co. KG Biberach an der Riss Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025296469","display_name":"Yoshiko Okai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I44892455","display_name":"Takeda (Japan)","ror":"https://ror.org/04hjbmv12","country_code":"JP","type":"company","lineage":["https://openalex.org/I44892455"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yoshiko Okai","raw_affiliation_strings":["Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa, Japan","institution_ids":["https://openalex.org/I44892455"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084535516","display_name":"Ravikumar Peri","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ravikumar Peri","raw_affiliation_strings":["Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063911514","display_name":"Amy Pointon","orcid":"https://orcid.org/0000-0001-9716-9811","observed_orcids":["https://orcid.org/0000-0001-9716-9811"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Amy Pointon","raw_affiliation_strings":["Research & Development, Clinical Pharmacology & Safety Sciences AstraZeneca Cambridge UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research & Development, Clinical Pharmacology & Safety Sciences AstraZeneca Cambridge UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077986587","display_name":"Yusheng Qu","orcid":"https://orcid.org/0000-0002-2684-0396","observed_orcids":["https://orcid.org/0000-0002-2684-0396"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yusheng Qu","raw_affiliation_strings":["Translational Safety & Bioanalytical Sciences, Amgen Research, Thousand Oaks, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Translational Safety & Bioanalytical Sciences, Amgen Research, Thousand Oaks, California, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012308714","display_name":"Ard C.H. Teisman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Ard Teisman","raw_affiliation_strings":["Global Safety Pharmacology Janssen Research & Development Beerse Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Safety Pharmacology Janssen Research & Development Beerse Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070564983","display_name":"Martin Traebert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Martin Traebert","raw_affiliation_strings":["Safety Pharmacology, Novartis Institute of Biomedical Research, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Safety Pharmacology, Novartis Institute of Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108505905","display_name":"Takashi Yoshinaga","orcid":"https://orcid.org/0000-0001-5969-0673","observed_orcids":["https://orcid.org/0000-0001-5969-0673"]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takashi Yoshinaga","raw_affiliation_strings":["Global Cardiovascular Assessment, Eisai Co., Ltd., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Cardiovascular Assessment, Eisai Co., Ltd., Tokyo, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039852503","display_name":"Gary A. Gintant","orcid":"https://orcid.org/0000-0003-4559-5514","observed_orcids":["https://orcid.org/0000-0003-4559-5514"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gary A. Gintant","raw_affiliation_strings":["Integrative Pharmacology, Abbvie, Inc, North Chicago, Illinois, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integrative Pharmacology, Abbvie, Inc, North Chicago, Illinois, USA","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113829375","display_name":"Derek J. Leishman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Derek J. Leishman","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5052012032","display_name":"Jean\u2010Pierre Valentin","orcid":"https://orcid.org/0000-0002-3599-9155","observed_orcids":["https://orcid.org/0000-0002-3599-9155"]},"institutions":[{"id":"https://openalex.org/I85722119","display_name":"UCB Pharma (Belgium)","ror":"https://ror.org/01n029866","country_code":"BE","type":"company","lineage":["https://openalex.org/I85722119"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Jean\u2010Pierre Valentin","raw_affiliation_strings":["UCB Biopharma SPRL, Braine-l'Alleud, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Biopharma SPRL, Braine-l'Alleud, Belgium","institution_ids":["https://openalex.org/I85722119"]}]}],"institutions":[],"countries_distinct_count":8,"institutions_distinct_count":22,"corresponding_author_ids":["https://openalex.org/A5001580477"],"corresponding_institution_ids":["https://openalex.org/I1320553840"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":{"value":3000,"currency":"USD","value_usd":3000},"fwci":2.1532,"has_fulltext":true,"cited_by_count":94,"citation_normalized_percentile":{"value":0.91237482,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"109","issue":"2","first_page":"310","last_page":"318"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10217","display_name":"Cardiac electrophysiology and arrhythmias","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10217","display_name":"Cardiac electrophysiology and arrhythmias","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/qtc-prolongation","display_name":"QTc prolongation","score":0.9210000038146973},{"id":"https://openalex.org/keywords/torsades-de-pointes","display_name":"torsades de pointes","score":0.8970000147819519},{"id":"https://openalex.org/keywords/drug-induced-arrhythmia","display_name":"drug-induced arrhythmia","score":0.7059999704360962},{"id":"https://openalex.org/keywords/ich-s7b","display_name":"ICH S7B","score":0.843999981880188},{"id":"https://openalex.org/keywords/ich-e14","display_name":"ICH E14","score":0.9929999709129333},{"id":"https://openalex.org/keywords/thorough-qt-study","display_name":"thorough QT study","score":0.7979999780654907},{"id":"https://openalex.org/keywords/ventricular-repolarization","display_name":"ventricular repolarization","score":0.8299999833106995},{"id":"https://openalex.org/keywords/drug-development","display_name":"drug development","score":0.3580000102519989},{"id":"https://openalex.org/keywords/regulatory-guidance","display_name":"regulatory guidelines","score":0.4099999964237213}],"concepts":[{"id":"https://openalex.org/C2779362680","wikidata":"https://www.wikidata.org/wiki/Q905000","display_name":"hERG","level":3,"score":0.8962975740432739},{"id":"https://openalex.org/C118441451","wikidata":"https://www.wikidata.org/wiki/Q12074763","display_name":"QT interval","level":2,"score":0.8912236094474792},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8103517293930054},{"id":"https://openalex.org/C2780486423","wikidata":"https://www.wikidata.org/wiki/Q1625433","display_name":"Torsades de pointes","level":3,"score":0.7183837294578552},{"id":"https://openalex.org/C2777672339","wikidata":"https://www.wikidata.org/wiki/Q7249641","display_name":"Prolongation","level":2,"score":0.5385066270828247},{"id":"https://openalex.org/C2776190711","wikidata":"https://www.wikidata.org/wiki/Q7398663","display_name":"Safety pharmacology","level":3,"score":0.5089938640594482},{"id":"https://openalex.org/C146403970","wikidata":"https://www.wikidata.org/wiki/Q205729","display_name":"Repolarization","level":3,"score":0.4776146113872528},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.43514424562454224},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4340238571166992},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.41316312551498413},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.383438378572464},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.30273985862731934},{"id":"https://openalex.org/C83743174","wikidata":"https://www.wikidata.org/wiki/Q423778","display_name":"Potassium channel","level":2,"score":0.08806189894676208},{"id":"https://openalex.org/C185263204","wikidata":"https://www.wikidata.org/wiki/Q1154774","display_name":"Electrophysiology","level":2,"score":0.0711413025856018}],"mesh":[{"descriptor_ui":"D000076722","descriptor_name":"Drug Development","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001145","descriptor_name":"Arrhythmias, Cardiac","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D004345","descriptor_name":"Drug Industry","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D004562","descriptor_name":"Electrocardiography","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008133","descriptor_name":"Long QT Syndrome","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D015507","descriptor_name":"Drugs, Investigational","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D016171","descriptor_name":"Torsades de Pointes","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1002/cpt.2029","doi":"https://doi.org/10.1002/cpt.2029","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpt.2029","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpt.2029","source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},{"id":"pmid:32866317","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32866317","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7891594","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7891594/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacol Ther","raw_type":"Text"},{"id":"pmh:oai:oak.novartis.com:42626","doi":null,"is_oa":true,"landing_page_url":"https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.2029","pdf_url":null,"source":{"id":"https://openalex.org/S4306400709","display_name":"The Novartis Repository (Novartis)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1283582996","host_organization_name":"Novartis (Switzerland)","host_organization_lineage":["https://openalex.org/I1283582996"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Article"}],"best_oa_location":{"id":"doi:10.1002/cpt.2029","doi":"https://doi.org/10.1002/cpt.2029","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpt.2029","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpt.2029","source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3082864643.pdf","grobid_xml":"https://content.openalex.org/works/W3082864643.grobid-xml"},"referenced_works_count":59,"referenced_works":["https://openalex.org/W878990122","https://openalex.org/W1136523086","https://openalex.org/W1505816740","https://openalex.org/W1591609796","https://openalex.org/W1759119712","https://openalex.org/W1911538625","https://openalex.org/W1967348830","https://openalex.org/W1970333224","https://openalex.org/W1972315245","https://openalex.org/W1975438579","https://openalex.org/W1978647133","https://openalex.org/W1979463298","https://openalex.org/W1979950725","https://openalex.org/W1995849691","https://openalex.org/W2000005501","https://openalex.org/W2002310806","https://openalex.org/W2012750516","https://openalex.org/W2016913639","https://openalex.org/W2026647000","https://openalex.org/W2039802311","https://openalex.org/W2048882411","https://openalex.org/W2049162091","https://openalex.org/W2058204042","https://openalex.org/W2059798273","https://openalex.org/W2066579438","https://openalex.org/W2067313345","https://openalex.org/W2073921281","https://openalex.org/W2074527519","https://openalex.org/W2087101821","https://openalex.org/W2088898515","https://openalex.org/W2104222112","https://openalex.org/W2109741389","https://openalex.org/W2113927644","https://openalex.org/W2159465837","https://openalex.org/W2170124735","https://openalex.org/W2269822816","https://openalex.org/W2277316067","https://openalex.org/W2302208827","https://openalex.org/W2399153108","https://openalex.org/W2463057329","https://openalex.org/W2588081908","https://openalex.org/W2590397724","https://openalex.org/W2602902911","https://openalex.org/W2625585441","https://openalex.org/W2768665057","https://openalex.org/W2771291368","https://openalex.org/W2810580674","https://openalex.org/W2888825293","https://openalex.org/W2893420171","https://openalex.org/W2954751346","https://openalex.org/W2955207560","https://openalex.org/W2986802075","https://openalex.org/W2988899860","https://openalex.org/W3001861750","https://openalex.org/W3013852583","https://openalex.org/W4292003663","https://openalex.org/W4292004352","https://openalex.org/W4294184268","https://openalex.org/W4406605739"],"related_works":["https://openalex.org/W7024959795","https://openalex.org/W3112394955","https://openalex.org/W2038481443","https://openalex.org/W2122926778","https://openalex.org/W4361019943","https://openalex.org/W1505816740","https://openalex.org/W4403605079","https://openalex.org/W3122597440","https://openalex.org/W4410218925","https://openalex.org/W4210294348"],"abstract_inverted_index":{"Defining":[0],"an":[1],"appropriate":[2],"and":[3,27,52,112,146,165,214,237,272],"efficient":[4],"assessment":[5,226,245],"of":[6,16,24,42,82,97,106,132,154,186,255,259,267],"drug-induced":[7],"corrected":[8],"QT":[9,73],"interval":[10],"(QTc)":[11],"prolongation":[12,145,169,189,262],"(a":[13],"surrogate":[14],"marker":[15],"torsades":[17],"de":[18],"pointes":[19],"arrhythmia)":[20],"remains":[21],"a":[22,103,219,240,256],"concern":[23],"drug":[25,200,274],"developers":[26],"regulators":[28],"worldwide.":[29],"In":[30,150],"use":[31],"for":[32,40,45,47,141,162,228,246],"over":[33],"15":[34],"years,":[35],"the":[36,80,120,152,184,253,265],"nonclinical":[37,93,130,158,177,213,250],"International":[38],"Council":[39],"Harmonization":[41],"Technical":[43],"Requirements":[44],"Pharmaceuticals":[46],"Human":[48],"Use":[49],"(ICH)":[50],"S7B":[51],"clinical":[53,110,143,172,187,191,215,224,260,269],"ICH":[54,138,155,234],"E14":[55,235],"guidances":[56],"describe":[57],"three":[58],"core":[59],"assays":[60,91],"(S7B:":[61],"in":[62,67,109,166,182,232,252],"vitro":[63],"hERG":[64,163],"current":[65],"&":[66],"vivo":[68,167],"QTc":[69,125,144,168,188,229,261,270],"studies;":[70],"E14:":[71],"thorough":[72],"study)":[74],"that":[75],"are":[76,193],"used":[77],"to":[78,84,102,123,210,217],"assess":[79],"potential":[81],"drugs":[83,108,115],"cause":[85],"delayed":[86,133],"ventricular":[87],"repolarization.":[88],"Incorporating":[89],"these":[90],"during":[92],"or":[94,202],"human":[95],"testing":[96],"novel":[98],"compounds":[99,247],"has":[100,208],"led":[101],"low":[104,199,257],"prevalence":[105,258],"QTc-prolonging":[107],"trials":[111],"no":[113],"new":[114],"having":[116],"been":[117],"removed":[118],"from":[119],"marketplace":[121],"due":[122],"unexpected":[124],"prolongation.":[126],"Despite":[127],"this":[128],"success,":[129],"evaluations":[131,192],"repolarization":[134],"still":[135],"minimally":[136],"influence":[137],"E14-based":[139],"strategies":[140],"assessing":[142,183],"defining":[147],"proarrhythmic":[148],"risk.":[149],"particular,":[151],"value":[153,181],"S7B-based":[156],"\"double-negative\"":[157],"findings":[159,251],"(low":[160],"risk":[161,185,225,244],"block":[164],"at":[170],"relevant":[171],"exposures)":[173],"is":[174],"underappreciated.":[175],"These":[176],"data":[178,216],"have":[179],"additional":[180],"when":[190],"limited":[194],"by":[195],"heart":[196],"rate":[197],"changes,":[198],"exposures,":[201],"high-dose":[203],"safety":[204],"considerations.":[205],"The":[206],"time":[207],"come":[209],"meaningfully":[211],"merge":[212],"enable":[218],"more":[220],"comprehensive,":[221],"but":[222],"flexible,":[223],"strategy":[227],"monitoring":[230],"discussed":[231],"updated":[233],"Questions":[236],"Answers.":[238],"Implementing":[239],"fully":[241],"integrated":[242],"nonclinical/clinical":[243],"with":[248],"double-negative":[249],"context":[254],"would":[263],"relieve":[264],"burden":[266],"unnecessary":[268],"studies":[271],"streamline":[273],"development.":[275]},"counts_by_year":[{"year":2026,"cited_by_count":9},{"year":2025,"cited_by_count":10},{"year":2024,"cited_by_count":26},{"year":2023,"cited_by_count":15},{"year":2022,"cited_by_count":18},{"year":2021,"cited_by_count":15},{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2020-09-08T00:00:00"}